Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3:14:1203437.
doi: 10.3389/fendo.2023.1203437. eCollection 2023.

The Russian registry of primary hyperparathyroidism, latest update

Natalia G Mokrysheva  1 , Anna K Eremkina  2 , Alina R Elfimova  2 , Elena V Kovaleva  2 , Anastasiia P Miliutina  2 , Ekaterina E Bibik  2 , Anna M Gorbacheva  2 , Ekaterina A Dobreva  2 , Irina S Maganeva  2 , Julia A Krupinova  2 , Rustam H Salimkhanov  2 , Lizaveta A Aboishava  2 , Elena V Karaseva  2 , Galina A Melnichenko  1 , Ivan I Dedov  1
Affiliations

The Russian registry of primary hyperparathyroidism, latest update

Natalia G Mokrysheva et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Until recently no major epidemiological research of primary hyperparathyroidism (PHPT) has been conducted in the Russian Federation, this led to the creation of the Russian online registry. The objective of this study is to estimate the clinical and biochemical profile, classical and non-classical complications, surgical intervention and medical therapy of the patients with different forms of PHPT in the Russian Federation.

Materials and methods: The cross-sectional, observational, continuous study was conducted at the Endocrinology Research Centre (Moscow). The present study explored retrospective data from 6003 patients submitted to the Registry between 12.12.2016 and 25.10.2022 from 81 regions of the Russian Federation (http://pgpt.clin-reg.ru/).

Results: The median age was 59 [60; 66] years with a female:male ratio of 11.7:1. Symptomatic PHPT was observed in 74.3% while asymptomatic form - only in 25.7% of cases. Bone pathology was the predominant clinical manifestation in 62.5% of cases (n=2293), mostly in combination with visceral complications 45.7% (n=1676). The majority of patients (63.3%) had combined visceral disorders including kidney damage in 51.8% and gastroduodenal erosions/ulcers in 32.3% of patients. Symptomatic patients were older (60 [53; 67] vs. 54 [45; 62] years, p<0.001) and had more severe biochemical alterations of calcium-phosphorus metabolism. Cardiovascular disease (СVD) was recorded in 48% of patients, among them the most frequent was arterial hypertension (up to 93.9%). A genetic test was conducted in 183 cases (suspicious for hereditary PHPT) revealing the mutations in MEN1, CDC73, RET genes in 107, 6 and 2 cases, respectively. Surgery was performed in 53.4% of patients with remission achievement in 87%, the relapse/persistence were recorded in 13% of cases. Histological examination revealed carcinoma in 4%, atypical adenoma in 2%, adenoma in 84% and hyperplasia in 11% of cases. Drug therapy was prescribed in 54.0% of cases, most often cholecalciferol.

Conclusion: The detection rate of PHPT has increased in the Russian Federation in recent years. This increase is associated with the start of online registration. However, the majority of patients remain symptomatic with significant alterations of phosphorus-calcium metabolism that indicates delayed diagnosis and requires further modifications of medical care.

Keywords: hypercalcemia; parathyroid hormone; prevalence; primary hyperparathyroidism; registry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Cumulative number of registered PHPT patients by year from 2019 to 2022.
Figure 2
Figure 2
Distribution of patients with PHPT by age.
Figure 3
Figure 3
The distribution of suspicious factors for hereditary PHPT.
See this image and copyright information in PMC

References

    1. Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab (2018) 103:3993–4004. doi: 10.1210/jc.2018-01225 - DOI - PMC - PubMed
    1. Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Amy Liu I-L, Harari A, et al. . Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab (2013) 98:1122–9. doi: 10.1210/jc.2012-4022 - DOI - PMC - PubMed
    1. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. . Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 21:171–7. doi: 10.1359/JBMR.050910 - DOI - PubMed
    1. Press DM, Siperstein AE, Berber E, Shin JJ, Metzger R, Jin J, et al. . The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery (2013) 154:1232–8. doi: 10.1016/j.surg.2013.06.051 - DOI - PubMed
    1. Walker MD, Rubin M, Silverberg SJ. Nontraditional manifestations of primary hyperparathyroidism. J Clin Densitom (2013) 16:40–7. doi: 10.1016/j.jocd.2012.11.008 - DOI - PMC - PubMed

Publication types

LinkOut - more resources